<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36127362</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Rate of speech decline in individuals with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>15713</StartPage><MedlinePgn>15713</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15713</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-19651-1</ELocationID><Abstract><AbstractText>Although speech declines rapidly in some individuals with amyotrophic lateral sclerosis (ALS), longitudinal changes in speech have rarely been characterized. The study objectives were to model the rate of decline in speaking rate and speech intelligibility as a function of disease onset site, sex, and age at onset in 166 individuals with ALS; and estimate time to speech loss from symptom onset. We also examined the association between clinical (speaking rate/intelligibility) measures and patient-reported measures of ALS progression (ALSFRS-R). Speech measures declined faster in the bulbar-onset group than in the spinal-onset group. The rate of decline was not significantly affected by sex and age. Functional speech was still maintained at 60&#xa0;months since disease onset for most patients with spinal onset. However, the time to speech loss was 23&#xa0;months based on speaking rate&#x2009;&amp;lt;&#x2009;120 (w/m) and 32&#xa0;months based on speech intelligibility&#x2009;&amp;lt;&#x2009;85% in individuals with ALS-bulbar onset. Speech measures were more responsive to functional decline than were the patient-reported measures. The findings of this study will inform future work directed toward improving speech prognosis in ALS, which is critical for determining the appropriate timing of interventions, providing appropriate counseling for patients, and evaluating functional changes during clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eshghi</LastName><ForeName>Marziye</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Depatment of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, The Athinoula A. Martinos Center for Biomedical Images, MGH, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunusova</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Speech-Language Pathology, Rehabilitation Sciences Institute, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KITE -Toronto Rehabilitation Institute - University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connaghan</LastName><ForeName>Kathryn P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Depatment of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Bridget J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Depatment of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maffei</LastName><ForeName>Marc F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Depatment of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M. Healey and AMG Center for ALS, MGH, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Clinical Research Unit, Montreal Neurological Institute &amp;amp; Hospital, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre de Recherche du CHU de Qu&#xe9;bec - Universit&#xe9; Laval, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Jordan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Depatment of Communication Sciences and Disorders, MGH Institute of Health Professions, Boston, MA, USA. jgreen2@mghihp.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Speech and Hearing Bioscience and Technology, Harvard University, Boston, USA. jgreen2@mghihp.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DC019179</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R15 DC018944</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23DC019179</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC017291</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DC009890</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R15DC018944</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DC016312</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013064" MajorTopicYN="N">Speech Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013065" MajorTopicYN="N">Speech Intelligibility</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36127362</ArticleId><ArticleId IdType="pmc">PMC9489769</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-19651-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-19651-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yorkston K, Strand E, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: Implications for the timing of intervention. J. Med. Speech. Lang. Pathol. 1993;1:35&#x2013;46.</Citation></Reference><Reference><Citation>Beukelman D, Fager S, Nordness A. Communication support for people with ALS. Neurol. Res. Int. 2011;2011:1&#x2013;6. doi: 10.1155/2011/714693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/714693</ArticleId><ArticleId IdType="pmc">PMC3096454</ArticleId><ArticleId IdType="pubmed">21603029</ArticleId></ArticleIdList></Reference><Reference><Citation>Creer S, Enderby P, Judge S, John A. Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need. Int. J. Lang. Commun. Disord. 2016;51:639&#x2013;653. doi: 10.1111/1460-6984.12235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1460-6984.12235</ArticleId><ArticleId IdType="pubmed">27113569</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee A, Bruening LM. Methods of communication at end of life for the person with amyotrophic lateral sclerosis. Top. Lang. Disord. 2012;32:168&#x2013;185. doi: 10.1097/TLD.0b013e31825616ef.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TLD.0b013e31825616ef</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla S, et al. Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure. J. Neurol. 2013;260:2242&#x2013;2255. doi: 10.1007/s00415-013-6955-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-6955-6</ArticleId><ArticleId IdType="pubmed">23736973</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, et al. ALSFRS-R score and its ratio: A useful predictor for ALS-progression. J. Neurol. Sci. 2008;275:69&#x2013;73. doi: 10.1016/j.jns.2008.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.07.016</ArticleId><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS) Cold Spring Harb. Perspect. Med. 2017;7:a024117. doi: 10.1101/cshperspect.a024117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024117</ArticleId><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N, Silani V. Neurodegenerative Diseases. Springer International Publishing; 2018. Genotypic and phenotypic heterogeneity in amyotrophic lateral sclerosis; pp. 279&#x2013;295.</Citation></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811. doi: 10.1212/WNL.0b013e3181b6bbbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bbbd</ArticleId><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Green JR, Wang J, Pattee G, Zinman L. A protocol for comprehensive assessment of bulbar dysfunction in amyotrophic lateral sclerosis (ALS) J. Vis. Exp. 2011 doi: 10.3791/2422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2422</ArticleId><ArticleId IdType="pmc">PMC3197394</ArticleId><ArticleId IdType="pubmed">21372794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkston, K., Beukelman, D. &amp; Hakel, M. Speech Intelligibility Test for Windows (1996).</Citation></Reference><Reference><Citation>Stipancic KL, et al. Two distinct clinical phenotypes of bulbar motor impairment in amyotrophic lateral sclerosis. Front. Neurol. 2021;12:715. doi: 10.3389/fneur.2021.664713.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.664713</ArticleId><ArticleId IdType="pmc">PMC8244731</ArticleId><ArticleId IdType="pubmed">34220673</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkonen T, Ruottinen H, Puhto R, Helminen M, Palmio J. Speech deterioration in amyotrophic lateral sclerosis (ALS) after manifestation of bulbar symptoms. Int. J. Lang. Commun. Disord. 2018;53:385&#x2013;392. doi: 10.1111/1460-6984.12357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1460-6984.12357</ArticleId><ArticleId IdType="pubmed">29159848</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: A speech subsystem approach. Behav. Neurol. 2015;2015:1&#x2013;11. doi: 10.1155/2015/183027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/183027</ArticleId><ArticleId IdType="pmc">PMC4468279</ArticleId><ArticleId IdType="pubmed">26136624</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball LJ, Willis A, Beukelman DR, Pattee GL. A protocol for identification of early bulbar signs in amyotrophic lateral sclerosis. J. Neurol. Sci. 2001;191:43&#x2013;53. doi: 10.1016/S0022-510X(01)00623-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00623-2</ArticleId><ArticleId IdType="pubmed">11676991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball LJ, Beukelman DR, Pattee GL. Timing of speech deterioration in people with amyotrophic lateral sclerosis. J. Med. Speech. Lang. Pathol. 2002;10:231&#x2013;235.</Citation></Reference><Reference><Citation>Barnett C, et al. Reliability and validity of speech &amp; pause measures during passage reading in ALS. Amyotroph. Lateral Scler. Front. Degener. 2020;21:42&#x2013;50. doi: 10.1080/21678421.2019.1697888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1697888</ArticleId><ArticleId IdType="pmc">PMC7080316</ArticleId><ArticleId IdType="pubmed">32138555</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra, S. et al. Authors Dr . Sanjay Kalra , MD , FRCPC Professor , Department of Medicine (Neurology ) Neurosciences and Mental Health Institute University of Alberta 7&#x2013;132F Clinical Sciences Building 11350&#x2013;83 Ave. (2020).</Citation></Reference><Reference><Citation>Yorkston, K., Beukelman, D. &amp; Hakel, M. Speech Intelligibility Test (SIT) for Windows. (2007).</Citation></Reference><Reference><Citation>Berry JD, et al. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotroph. Lateral Scler. Front. Degener. 2013;14:162&#x2013;168. doi: 10.3109/21678421.2012.762930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Stipancic KL, et al. &#x201c;You Say Severe, I Say Mild&#x201d;: Toward an empirical classification of dysarthria severity. J. Speech Lang. Hear. Res. 2021;64:4718&#x2013;4735. doi: 10.1044/2021_JSLHR-21-00197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2021_JSLHR-21-00197</ArticleId><ArticleId IdType="pmc">PMC9150682</ArticleId><ArticleId IdType="pubmed">34762814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Early symptom progression rate is related to ALS outcome: A prospective population-based study. Neurology. 2002;59:99&#x2013;103. doi: 10.1212/WNL.59.1.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.1.99</ArticleId><ArticleId IdType="pubmed">12105314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38&#x2013;43. doi: 10.1212/01.WNL.0000148648.38313.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148648.38313.64</ArticleId><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia TP, Marder K. Statistical approaches to longitudinal data analysis in neurodegenerative diseases: huntington&#x2019;s disease as a model. Curr. Neurol. Neurosci. Rep. 2017;17:14. doi: 10.1007/s11910-017-0723-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0723-4</ArticleId><ArticleId IdType="pmc">PMC5633048</ArticleId><ArticleId IdType="pubmed">28229396</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenberghs G, Verbeke G. A review on linear mixed models for longitudinal data, possibly subject to dropout. Stat. Model. 2001;1:235&#x2013;269. doi: 10.1177/1471082X0100100402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1471082X0100100402</ArticleId></ArticleIdList></Reference><Reference><Citation>Niimi MNS. Changes over time in dysarthric patients with amyotrophic lateral sclerosis (ALS): A study of changes in speaking rate and maximum repetition rate (MRR) Clin. Linguist. Phon. 2000;14:485&#x2013;497. doi: 10.1080/026992000750020323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/026992000750020323</ArticleId></ArticleIdList></Reference><Reference><Citation>Daghlas I, Lever TE, Leary E. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials. Amyotroph. Lateral Scler. Front. Degener. 2018;19:206&#x2013;211. doi: 10.1080/21678421.2017.1418001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1418001</ArticleId><ArticleId IdType="pubmed">29260911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:381&#x2013;385. doi: 10.1136/jnnp-2016-314661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314661</ArticleId><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Connaghan, K. P. et al. Use of Beiwe Smartphone App to Identify and Track Speech Decline in Amyotrophic Lateral Sclerosis (ALS). In Interspeech 2019 4504&#x2013;4508 (ISCA, 2019). 10.21437/Interspeech.2019-3126.</Citation></Reference><Reference><Citation>Kent RD, et al. Impairment of speech intelligibility in men with amyotrophic lateral sclerosis. J. Speech Hear. Disord. 1990;55:721&#x2013;728. doi: 10.1044/jshd.5504.721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/jshd.5504.721</ArticleId><ArticleId IdType="pubmed">2232752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishio M, Niimi S. Changes over time in dysarthric patients with amyotrophic lateral sclerosis(ALS). II. A study of changes in speaking rate and maximum repetition Rate(MRR) Jpn. J. Logop. Phoniatr. 1999;40:8&#x2013;16. doi: 10.5112/jjlp.40.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.5112/jjlp.40.8</ArticleId></ArticleIdList></Reference><Reference><Citation>del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: A population-based study. Neurology. 2003;60:813&#x2013;819. doi: 10.1212/01.WNL.0000049472.47709.3B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000049472.47709.3B</ArticleId><ArticleId IdType="pubmed">12629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, et al. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995&#x2013;2010. PLoS ONE. 2013;8:e74733. doi: 10.1371/journal.pone.0074733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074733</ArticleId><ArticleId IdType="pmc">PMC3786977</ArticleId><ArticleId IdType="pubmed">24098664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, et al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J. Neurol. Neurosurg. Psychiatry. 2013;84:766&#x2013;773. doi: 10.1136/jnnp-2012-302674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302674</ArticleId><ArticleId IdType="pubmed">23085933</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E, et al. Combined tissue-fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci. Rep. 2019;9:4478. doi: 10.1038/s41598-019-40632-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40632-4</ArticleId><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball LJ, Beukelman DR, Pattee G. AAC clinical decision making for persons with ALS. Perspect. Augment. altern. commun. 2002;11:7&#x2013;13. doi: 10.1044/aac11.1.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/aac11.1.7</ArticleId></ArticleIdList></Reference><Reference><Citation>Londral AR, Encarnacao P, Azevedo L. Selecting AAC devices for persons with ALS taking into consideration the disease progression. Assist. Technol. Res. Ser. 2009;25:12&#x2013;17.</Citation></Reference><Reference><Citation>Magnus T, et al. Disease progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle Nerve. 2002;25:709&#x2013;714. doi: 10.1002/mus.10090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10090</ArticleId><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>Muddasir Qureshi M, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS) Amyotroph. Lateral Scler. 2006;7:173&#x2013;182. doi: 10.1080/14660820600640596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820600640596</ArticleId><ArticleId IdType="pubmed">16963407</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison KM, et al. The diagnostic utility of patient-report and speech-language pathologists&#x2019; ratings for detecting the early onset of bulbar symptoms due to ALS. Amyotroph. Lateral Scler. Front. Degener. 2017;18:358&#x2013;366. doi: 10.1080/21678421.2017.1303515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1303515</ArticleId><ArticleId IdType="pmc">PMC5530595</ArticleId><ArticleId IdType="pubmed">28355886</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann GM, et al. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. npj Digit. Med. 2020;3:132. doi: 10.1038/s41746-020-00335-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00335-x</ArticleId><ArticleId IdType="pmc">PMC7555482</ArticleId><ArticleId IdType="pubmed">33083567</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>